{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:08:33Z","timestamp":1780387713091,"version":"3.54.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The prognosis of patients with multiple myeloma (MM) is variable and partly depends on their cardiovascular status. The presence of arrhythmias can lead to worse outcomes. Therefore, this study aimed to evaluate the potential of heart rate (HR) and hypertension in predicating the outcomes of MM patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study retrospectively enrolled patients with MM between January 1, 2010, and December 31, 2018, at the First Affiliated Hospital of Xi'an Jiaotong University. The endpoint was all-cause mortality. The Pearson's chi-square test was used to assess the association between hypertension and outcomes. Univariate and multivariate Cox proportional hazards models were developed to evaluate the relationship between HR and all-cause mortality.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 386 patients were included. The mean HR was 83.8 \u00b1 23.1 beats per minute (bpm). Patients with HR &amp;gt;100 bpm had a higher all-cause mortality (79.4%, 50\/63) than those with 60 \u2264 HR \u2264 100 bpm (39.9%, 110\/276) and &amp;lt;60 bpm (19.1%, 9\/47) (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). Subgroup analysis based on the International Staging System and sex revealed similar relationships (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). When stratified by age, patients with HR &amp;gt;100 bpm had higher all-cause mortality than those with a lower HR when age was &amp;lt;65 years or 65\u201375 years (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) but not &amp;gt;75 years. The proportion of patients with hypertension was 54.7% (211\/386). However, hypertension was not associated with all-cause mortality in MM patients (\u03c7<jats:sup>2<\/jats:sup>=1.729, <jats:italic>p<\/jats:italic> &amp;gt; 0.05). MM patients with HR &amp;gt;100 bpm had the highest all-cause mortality.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> The prognostic potential of HR may be useful in aiding risk stratification and promoting the management of these patients.<\/jats:p>","DOI":"10.3389\/fcvm.2021.681484","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T13:46:37Z","timestamp":1632750397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic Potential of Heart Rate and Hypertension in Multiple Myeloma Patients"],"prefix":"10.3389","volume":"8","author":[{"given":"Jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhuo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cncr.30003","article-title":"Changes in the survival of older patients with hematologic malignancies in the early 21st century","volume":"122","author":"Pulte","year":"2016","journal-title":"Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12871-018-0558-9","article-title":"Elevated preoperative heart rate associated with increased risk of cardiopulmonary complications after resection for lung cancer","volume":"18","author":"Fu","year":"2018","journal-title":"BMC Anesthesiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/ejhf.670","article-title":"Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study","volume":"18","author":"Anker","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"B9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.numecd.2017.04.004","article-title":"Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality\u2014a systematic review and dose-response meta-analysis of prospective studies","volume":"27","author":"Aune","year":"2017","journal-title":"Nutr Metab Cardiovas Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1007\/s12325-020-01343-9","article-title":"Prognostic potential of electrocardiographic parameters in patients with multiple myeloma: a retrospective analysis of the multiple myeloma population","volume":"37","author":"Wang","year":"2020","journal-title":"Adv Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","article-title":"Multiple myeloma, version 3.2017, nccn clinical practice guidelines in oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J Natl Compr Canc Netw."},{"key":"B12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension","volume":"16","year":"2019","journal-title":"J Geriatr Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/jco.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjh.15800","article-title":"Substratification of patients with newly diagnosed standard-risk multiple myeloma","volume":"185","author":"Binder","year":"2019","journal-title":"Br J Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas\u2014current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of cardiovascular risk in patients with multiple myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-019-0784-4","article-title":"Cardiovascular complications associated with multiple myeloma therapies: incidence, pathophysiology, and management","volume":"21","author":"Patel","year":"2019","journal-title":"Curr Oncol Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ijcard.2015.10.083","article-title":"Burden of arrhythmias in patients with multiple myeloma","volume":"203","author":"Shah","year":"2016","journal-title":"Int J Cardiol."},{"key":"B20","unstructured":"ACC NewsStory\n          Tachycardia May Signal Increased Mortality Risk in Cancer Patients2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","article-title":"Bradycardia during therapy for multiple myeloma with thalidomide","volume":"93","author":"Fahdi","year":"2004","journal-title":"Am J Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.hfc.2011.03.009","article-title":"Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment","volume":"7","author":"Seldin","year":"2011","journal-title":"Heart Fail Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/14779072.2017.1409114","article-title":"Cardiovascular complications of multiple myeloma in the elderly","volume":"15","author":"Mathur","year":"2017","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","article-title":"Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation","volume":"19","author":"Singla","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1753944712464102","article-title":"Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors","volume":"6","author":"Sureddi","year":"2012","journal-title":"Ther Adv Cardiovasc Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan","year":"1997","journal-title":"Leuk Lymphoma."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/1097-0142(19910615)67:12<3150::aid-cncr2820671236>3.0.co;2-u","article-title":"Prognostic factors in multiple myeloma","volume":"67","author":"Cherng","year":"1991","journal-title":"Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","article-title":"Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System","volume":"126","author":"Kuiper","year":"2015","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ctrv.2015.07.005","article-title":"Clinical characteristics of patients with relapsed multiple myeloma","volume":"41","author":"Dimopoulos","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12882","article-title":"Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European myeloma network and the Italian society of arterial hypertension","volume":"286","author":"Bringhen","year":"2019","journal-title":"J Int Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12885-016-2955-0","article-title":"Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study","volume":"16","author":"Chari","year":"2016","journal-title":"BMC Cancer."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.681484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T13:46:43Z","timestamp":1632750403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.681484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2021.681484"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.681484","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"article-number":"681484"}}